Literature DB >> 16115232

Serous borderline tumours of the ovary.

R J Kurman1, J D Seidman, I-M Shih.   

Abstract

Serous borderline tumours of the ovaryIn this Expert Opinion we have invited articles from two leading groups, to discuss serous borderline tumours (serous tumours of low malignant potential) of the ovary from their own perspectives. Controversy remains over heterogeneity within this group of tumours and their relationship to ovarian cancer. Our authors discuss the histopathological classification of these tumours in relation to morphological appearances, molecular and clinical data. The significance of a micropapillary pattern is discussed, and issues related to extra-ovarian implants.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16115232     DOI： 10.1111/j.1365-2559.2005.02186.x

Source DB:  PubMed          Journal:  Histopathology        ISSN： 0309-0167            Impact factor:   5.087


  9 in total

1.  Prognosis and prognostic factors of the micropapillary pattern in patients treated for stage II and III serous borderline tumors of the ovary.

Authors:  Catherine Uzan; Aminata Kane; Annie Rey; Sebastien Gouy; Sophie Camatte; Patricia Pautier; Catherine Lhommé; Christine Haie-Meder; Pierre Duvillard; Philippe Morice
Journal:  Oncologist       Date:  2011-01-27

2.  Whole exome sequence analysis of serous borderline tumors of the ovary.

Authors:  Jeff Boyd; Biao Luo; Suraj Peri; Beth Wirchansky; Lucinda Hughes; Caitlin Forsythe; Hong Wu
Journal:  Gynecol Oncol       Date:  2013-06-14       Impact factor: 5.482

3.  Long-term Behavior of Serous Borderline Tumors Subdivided Into Atypical Proliferative Tumors and Noninvasive Low-grade Carcinomas: A Population-based Clinicopathologic Study of 942 Cases.

Authors:  Russell Vang; Charlotte G Hannibal; Jette Junge; Kirsten Frederiksen; Susanne K Kjaer; Robert J Kurman
Journal:  Am J Surg Pathol       Date:  2017-06       Impact factor: 6.394

4.  Biomarker expression in normal fimbriae: Comparison of high- and low-grade serous ovarian carcinoma.

Authors:  Zhang Xuyin; Ding Jingxin; Tao Xiang; Jia Luoqi; Hua Keqin
Journal:  Oncol Lett       Date:  2012-08-23       Impact factor: 2.967

5.  Risk factors for recurrence of ovarian borderline tumors.

Authors:  K K Shih; Q Zhou; J Huh; J C Morgan; A Iasonos; C Aghajanian; D S Chi; R R Barakat; N R Abu-Rustum
Journal:  Gynecol Oncol       Date:  2010-12-10       Impact factor: 5.482

6.  Patterns of recurrence and role of adjuvant chemotherapy in stage II-IV serous ovarian borderline tumors.

Authors:  Karin K Shih; Qin C Zhou; Carol Aghajanian; Jae Huh; Robert A Soslow; Jessica C Morgan; Alexia Iasonos; Dennis S Chi; Richard R Barakat; Nadeem R Abu-Rustum
Journal:  Gynecol Oncol       Date:  2010-08-16       Impact factor: 5.482

7.  Mutational status of KRAS, NRAS, and BRAF in primary clear cell ovarian carcinoma.

Authors:  Gian Franco Zannoni; Giuseppina Improta; Gaia Chiarello; Angela Pettinato; Marco Petrillo; Paolo Scollo; Giovanni Scambia; Filippo Fraggetta
Journal:  Virchows Arch       Date:  2014-06-03       Impact factor: 4.064

8.  Immunohistochemical profiling of benign, low malignant potential and low grade serous epithelial ovarian tumors.

Authors:  Véronique Ouellet; Tak Hay Ling; Karine Normandin; Jason Madore; Christian Lussier; Véronique Barrès; Dimcho Bachvarov; Claudine Rancourt; Patricia N Tonin; Diane M Provencher; Anne-Marie Mes-Masson
Journal:  BMC Cancer       Date:  2008-11-26       Impact factor: 4.430

9.  KRAS, BRAF genotyping reveals genetic heterogeneity of ovarian borderline tumors and associated implants.

Authors:  Sabine Heublein; Katinka Grasse; Harald Hessel; Alexander Burges; Miriam Lenhard; Jutta Engel; Thomas Kirchner; Udo Jeschke; Doris Mayr
Journal:  BMC Cancer       Date:  2013-10-18       Impact factor: 4.430
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.